NCT04529811View on ClinicalTrials.gov

Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

May 9, 2021

Study Completion Date

May 9, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

Rifaximin Novel Formulation

DRUG

Placebo

Trial Locations (1)

Unknown

Auckland Clinical Studies, Grafton

All Listed Sponsors

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT04529811 - Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers | Biotech Hunter | Biotech Hunter